Skip To Main Content
Elizabeth Lee on Muck Rack

Elizabeth Lee

As seen in: Nature, MDPI, SAGE Publishing, BioRxiv, Cell Press, ONCOLOGY journal, Texas Medical Center, OncLive, Archives of Pathology, Oncology Nursing News and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Elizabeth

Contact Elizabeth, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Atomistic characterization of the maturation mechanisms in the HIV-1 capsid domain

|
By Caroline Cannistra, Ethan Wang, Elizabeth Lee, Alvin Yu
| Nature Verified
Abstract During HIV-1 maturation, capsid proteins (CA) are proteolytically cleaved from the immature Gag lattice and undergo conformational transitions in which the amino-terminal and carboxy-terminal domains rearrange into mature conformations prior to assembling into fullerene complexes. Little is known, however, of the structural transitions and energetic principles governing this transformation.
Open in Who Shared Issue with article?

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial

|
By Rebecca Porter, Yinglu Zhou, Nebiyat Eskndir, Martin Hayes, Madeline Polak, Elizabeth Lee, Carolyn Krasner, Susana Campos, Alexi A. Wright, Joyce Liu, Elizabeth Stover, Hannah Sawyer, Niya Xiong, Kathleen L. Pfaff, Scott J. Rodig, Nabihah Tayob, Susan Zweizig, Veena John, Ursula Matulonis, Panagiotis A. Konstantinopoulos, Jennifer Veneris
| Nature Verified
Abstract Immune checkpoint inhibitors (ICI) synergize preclinically with antibody drug conjugates (ADC), harboring anti-tubulin maytansinoid payloads. We conducted an investigator-initiated, single-arm, phase 2 trial of mirvetuximab soravtansine (MIRV), a folate receptor alpha (FOLR1/FRα)-targeting ADC with the maytansinoid payload, DM4, combined with pembrolizumab in female patients with recurrent FOLR1-expressing serous endometrial cancer (EC, NCT03835819).
Open in Who Shared Issue with article?

Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates

|
By Patricia Jakel, Kelly Grosklags, Elizabeth Lee
| Oncology Nursing News Verified
Recent clinical developments in non-small cell lung cancer (NSCLC) highlight the critical roles of treatment timing, comprehensive molecular profiling, and innovative delivery systems in improving patient outcomes.
Open in Who Shared Issue with article?
See all 37 licensed articles (42 Total)